Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | CDC7 | O00311 | 1/20 | 0.56 |
| ▸ | EEF2K | O00418 | 1/20 | 0.56 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.56 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8043492 | 0.98 | HTR6 (0.97) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7836014 | 0.91 | HTR6 (0.84) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL8056189 | 0.91 | HTR6 (0.84) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7832372 | 0.91 | HTR6 (0.82) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL8054961 | 0.90 | HTR6 (0.82) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL8056185 | 0.90 | HTR6 (0.82) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7836526 | 0.90 | HTR6 (0.82) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL8055906 | 0.89 | HTR6 (0.80) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL7839560 | 0.89 | HTR6 (0.80) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7836318 | 0.88 | HTR6 (0.78) | HTR6MAPTALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| EP-1971334-A2 | COMBINATION OF ACHE INHIBITOR AND 5-HT6 ANTAGONIST FOR THE TREATMENT OF COGNITIVE DYSFUNCTION | Wyeth a Corporation of the State of Delaware (US) | 2008-09-24 | — | — | EP | claimed |
| WO-2007087151-A2 | COMBINATION OF ACHE INHIBITOR AND 5-HT6 ANTAGONIST FOR THE TREATMENT OF COGNITIVE DYSFUNCTION | WYETH (US) | 2007-08-02 | — | — | WO | claimed |
| US-20070167431-A1 | Method for the treatment of cognitive dysfunction | WYETH (US) | 2007-07-19 | — | — | US | claimed |
| EP-1799306-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-06-27 | — | — | EP | claimed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | claimed |
| EP-0815861-B1 | Sulphonamides and their use | HOFFMANN LA ROCHE (CH) | 2001-09-19 | — | — | EP | claimed |
| EP-0815861-A1 | Sulphonamides and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-07 | — | — | EP | claimed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4634194-A1 | SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4634193-A1 | SUBSTITUTED DIHYDROPYRROLO[3, 4-D]PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12421242-B2 | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions | Karuna Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12398119-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-6030976-A | SELECTIVE AFFINITY TO 5HT-6 RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS; ALZHEIMER'S DISEASE, PSYCHOSES, SCHIZOPHRENIA, MANIC DEPRESSIONS, MEMORY DISORDERS, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS AND HUNTINGTON'S DISEASE | HOFFMAN-LA ROCHE INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-5998665-A | THERAPY FOR NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5939451-A | INDOL-4-YL-BENZENESULFONAMIDES AS ACTIVE MATERIAL TREATING MALARIA, BACTERIAL INFECTION, NEUROLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-08-17 | — | — | US | disclosed |
| US-5932599-A | 4-AMINO-N-(PYRIDINYL-4-YL)-BENZENESULFONAMIDES AS ACTIVE MATERIAL TREATING MALARIA, BACTERIAL INFECTION, NEUROLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0815861-A1 | Sulphonamides and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398119-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | HTR6 1177/4885MAPT 403/4885ALDH1A1 1350/4885 |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | HTR6, HTR2A, HTR2C | HTR6 1/4885MAPT 381/4885ALDH1A1 3003/4885 |
| US-20070167431-A1 | Method for the treatment of cognitive dysfunction | ACHE, BCHE, HTR6 | HTR6 3/4885MAPT 285/4885ALDH1A1 1244/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | HTR6 376/4885MAPT 377/4885ALDH1A1 687/4885 |
| US-12421242-B2 | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions | CHRM3, CHRM4, CHRM2 | HTR6 32/4885MAPT 487/4885ALDH1A1 1284/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | HTR6 35/4885MAPT 2245/4885ALDH1A1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.